Cartesian Therapeutics Inc (RNAC)
19.12
-0.56
(-2.85%)
USD |
NASDAQ |
Nov 04, 16:00
19.12
0.00 (0.00%)
After-Hours: 20:00
Cartesian Therapeutics Debt to Equity Ratio: 0.00 for June 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
Date | Value |
---|---|
June 30, 2024 | 0.00 |
March 31, 2024 | 0.00 |
December 31, 2023 | 0.00 |
September 30, 2023 | 0.00 |
June 30, 2023 | 0.367 |
March 31, 2023 | 0.3546 |
December 31, 2022 | 0.2799 |
September 30, 2022 | 0.3073 |
June 30, 2022 | 0.2893 |
March 31, 2022 | 0.4616 |
December 31, 2021 | 1.138 |
September 30, 2021 | -1.358 |
June 30, 2021 | -5.974 |
March 31, 2021 | -1.278 |
December 31, 2020 | -1.377 |
September 30, 2020 | -3.331 |
June 30, 2020 | -1.136 |
March 31, 2020 | -1.925 |
Date | Value |
---|---|
December 31, 2019 | 2.251 |
September 30, 2019 | -4.258 |
June 30, 2019 | 384.79 |
March 31, 2019 | 1.448 |
December 31, 2018 | -3.947 |
September 30, 2018 | 2.130 |
June 30, 2018 | 0.8743 |
March 31, 2018 | 0.5081 |
December 31, 2017 | 0.4061 |
September 30, 2017 | 0.322 |
June 30, 2017 | 0.1323 |
March 31, 2017 | 0.2771 |
December 31, 2016 | 0.2192 |
September 30, 2016 | 0.183 |
June 30, 2016 | 0.1732 |
March 31, 2016 | 0.8257 |
December 31, 2015 | -0.1018 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
-5.974
Minimum
Jun 2021
2.251
Maximum
Dec 2019
-0.5752
Average
--
Median
Sep 2023
Debt to Equity Ratio Benchmarks
Alnylam Pharmaceuticals Inc | 31.64 |
Amgen Inc | 8.024 |
Johnson & Johnson | 0.5096 |
Regeneron Pharmaceuticals Inc | 0.0677 |
NovaBay Pharmaceuticals Inc | -1.128 |
Debt to Equity Ratio Related Metrics
Total Assets (Quarterly) | 347.74M |
Total Liabilities (Quarterly) | 449.20M |
Shareholders Equity (Quarterly) | -101.46M |
Current Ratio | 4.778 |
Net Debt Paydown Yield | 1.10% |